Author:
McCleary-Wheeler Angela L.,Fiaux Patrick C.,Ruiz-Perez Carlos A.,McLennan Lisa M.,Tynan John A.,Hicks Susan C.,Rafalko Jill M.,Grosu Daniel S.,Chibuk Jason,O’Kell Allison L.,Cohen Todd A.,Flesner Brian K.,Chorny Ilya,Tsui Dana W.Y.,Kruglyak Kristina M.,Flory Andi
Abstract
AbstractObjectiveThe purpose of this study was to evaluate the performance of a next-generation sequencing-based liquid biopsy test for cancer monitoring in dogs.SamplesPre- and post-operative blood samples were collected prospectively from dogs with confirmed cancer diagnoses originally enrolled in the CANcer Detection in Dogs (CANDiD) study. A subset of these dogs also had longitudinal blood samples collected for recurrence monitoring.MethodsAll patients had a pre-operative blood sample collected (after diagnosis but prior to surgical intervention) in which a cancer signal was detected, and had at least one post-operative sample collected. Clinical data were collected for all patients and used to assign a clinical disease status for each follow-up visit.ResultsFollowing excisional surgery, in the absence of clinical residual disease at the post-operative visit, patients withCancer Signal Detectedresults at that visit were 1.95-times as likely to have clinical recurrence within 6 months compared to patients withCancer Signal Not Detectedresults. In the subset of patients with longitudinal liquid biopsy samples that had clinical recurrence documented during the study period, 73% (8/11; 95% CI: 39 – 93%) of patients hadCancer Signal Detectedin blood prior to or concomitant with clinical recurrence; in the 6 patients where molecular recurrence was detected prior to clinical recurrence, the median lead time was 168 days (range: 47 – 238).Clinical RelevanceNext-generation sequencing-based liquid biopsy is a non-invasive tool for cancer monitoring in dogs that can be used as an adjunct to current standard-of-care clinical assessment methods.
Publisher
Cold Spring Harbor Laboratory